Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
- PMID: 19286905
- DOI: 10.1136/ard.2008.101964
Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions
Abstract
In severe untreated rheumatoid arthritis (RA), reductions in high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol and total cholesterol have been noted; this is in line with findings in other pathologies/conditions associated with inflammation or infection, such as sepsis, cancer, trauma or the postoperative period. Although the precise mechanisms remain to be established, cytokine-induced activation of the reticuloendothelial system is potentially critical to such changes. Consequently, dampening of inflammation in severe RA-as occurs with several biologics-may lead to increases, not only in high-density lipoprotein-cholesterol, but also with other lipid moieties, including total and low-density lipoprotein-cholesterol and, perhaps, triglycerides. This concept is consistent with findings following antitumour necrosis factor treatment and interleukin-6 receptor inhibition in patients with RA. At the same time, it is increasingly apparent that potent dampening of inflammation, however achieved, broadly reduces the risk of cardiovascular disease in RA. Therefore, changes in lipid profiles, particularly increases in cholesterol and triglycerides that occur with treatments for severe inflammation, may not represent increased cardiovascular risk as in the usual understanding of lipid-level elevations in individuals without significant inflammation. Rather, changes in lipid levels, in part or largely, may represent a predictable response to attenuation of inflammation. These observations are increasingly important clinically and should aid in the understanding and interpretation of lipid changes under inflammatory conditions, as well as in the context of potent anti-inflammatory interventions.
Similar articles
-
Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.J Rheumatol. 2009 Jul;36(7):1365-70. doi: 10.3899/jrheum.080928. Epub 2009 Apr 15. J Rheumatol. 2009. PMID: 19369465
-
Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.Semin Arthritis Rheum. 2009 Apr;38(5):372-81. doi: 10.1016/j.semarthrit.2008.01.015. Epub 2008 Apr 18. Semin Arthritis Rheum. 2009. PMID: 18395771 Review.
-
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.Ann Rheum Dis. 2009 Jun;68(6):868-72. doi: 10.1136/ard.2008.092171. Epub 2008 Jul 17. Ann Rheum Dis. 2009. PMID: 18635596 Clinical Trial.
-
Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.Scand J Rheumatol. 2006 Mar-Apr;35(2):107-11. doi: 10.1080/03009740500474578. Scand J Rheumatol. 2006. PMID: 16641043
-
Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.Expert Opin Pharmacother. 2008 May;9(7):1121-8. doi: 10.1517/14656566.9.7.1121. Expert Opin Pharmacother. 2008. PMID: 18422470 Review.
Cited by
-
Association of oxidative stress markers with atherogenic index of plasma in adult sickle cell nephropathy.Anemia. 2012;2012:767501. doi: 10.1155/2012/767501. Epub 2012 Apr 18. Anemia. 2012. PMID: 22570773 Free PMC article.
-
Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.Drug Des Devel Ther. 2018 Dec 19;13:57-70. doi: 10.2147/DDDT.S150580. eCollection 2019. Drug Des Devel Ther. 2018. PMID: 30587928 Free PMC article. Review.
-
Anti-arthritic effect of GN1, a novel synthetic analog of glucosamine, in the collagen-induced arthritis model in rats.Inflamm Res. 2011 Dec;60(12):1113-20. doi: 10.1007/s00011-011-0375-9. Epub 2011 Aug 27. Inflamm Res. 2011. PMID: 21874354
-
Vitamin D Receptor Polymorphism and DHCR7 Contribute to the Abnormal Interplay Between Vitamin D and Lipid Profile in Rheumatoid Arthritis.Sci Rep. 2019 Feb 22;9(1):2546. doi: 10.1038/s41598-019-38756-8. Sci Rep. 2019. PMID: 30796319 Free PMC article.
-
Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.Arthritis Care Res (Hoboken). 2015 Apr;67(4):457-66. doi: 10.1002/acr.22483. Arthritis Care Res (Hoboken). 2015. PMID: 25302481 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials